BRIEF: InnoCare revenue jumps 37% in 2024 on strong lymphoma drug sales
InnoCare Pharma Ltd. (9969.HK; 688428.SH) said on Thursday its revenue rose 37% last year to 1.01 billion yuan ($138 million), fueled by strong gains for Orelabrutinib, its drug used to…
Recent Articles
BRIEF: InnoCare revenue jumps 37% in 2024 on strong lymphoma drug sales
9969.HK
688428.SHG
